|
|
|
(a)(1)(G)
|
|
Solicitation/Recommendation Statement on Schedule 14D-9 (incorporated by reference to the Companys Solicitation/Recommendation Statement on Schedule
14D-9 filed on September 14, 2020)
|
|
|
(a)(5)(A)
|
|
Joint Press Release issued by Akcea Therapeutics, Inc. and Ionis Pharmaceuticals, Inc. on August 31, 2020 (incorporated by reference to Exhibit 99.1 to the Companys Current Report on Form
8-K filed on August 31, 2020).
|
|
|
(a)(5)(B)
|
|
Letter, dated August 31, 2020, from Damien McDevitt, the Companys Chief Executive Officer, and B. Lynne Parshall, Chair of the Companys Board of Directors, to the Employees of the Company (incorporated by reference
to the Companys Solicitation/Recommendation Statement on Schedule 14D-9 filed on August 31, 2020).
|
|
|
(b)
|
|
Not applicable.
|
|
|
(c)(1)
|
|
Opinion of Cowen and Company LLC, dated August 30, 2020 (incorporated by reference to Annex B attached to the Companys Solicitation/Recommendation Statement on Form 14D-9 filed on
September 14, 2020).
|
|
|
(c)(2)#
|
|
Presentation titled Project Avalanche Presentation to the Affiliate Transactions Committee, dated August 19, 2020, of Cowen and Company, LLC to the Affiliate Transactions Committee of the Board of Directors
of the Company.
|
|
|
(c)(3)#
|
|
Presentation titled Project Avalanche Presentation to the Affiliate Transactions Committee, dated August 29, 2020, of Cowen and Company, LLC to the Affiliate Transactions Committee of the Board of Directors
of the Company.
|
|
|
(c)(4)#
|
|
Presentation titled Project Avalanche Presentation to the Affiliate Transactions Committee, dated August 30, 2020, of Cowen and Company, LLC to the Affiliate Transactions Committee of the Board of Directors
of the Company.
|
|
|
(c)(5)#
|
|
Presentation titled Project Avalanche Final Document, dated August 14, 2020, of ClearView Healthcare Partners LLC to the Affiliate Transactions Committee of the Board of Directors of the Company.
|
|
|
(d)(1)
|
|
Agreement and Plan of Merger, by and among Akcea Therapeutics, Inc., Ionis Pharmaceuticals, Inc. and Avalanche Merger Sub, Inc., dated August 30, 2020 (incorporated by reference to Exhibit 2.1 to the Companys Current
Report on Form 8-K filed on August 31, 2020).
|
|
|
(d)(2)
|
|
Non-Disclosure Agreement, by and between Akcea Therapeutics, Inc. and Ionis Pharmaceuticals, Inc., dated July 17, 2020 (incorporated by reference to Exhibit (e)(2) to the Companys
Solicitation/Recommendation Statement on Form 14D-9 filed on September 14, 2020)
|
|
|
(d)(3)
|
|
Senior Unsecured Line of Credit Agreement, by and between Akcea Therapeutics, Inc. and Ionis Pharmaceuticals, Inc., dated January 18, 2017 (incorporated by reference to Exhibit 10.6 to the Companys Registration Statement
on Form S-1 filed on March 27, 2017)
|
|
|
(d)(4)
|
|
Development, Commercialization, Collaboration, and License Agreement, by and between Akcea Therapeutics, Inc. and Ionis Pharmaceuticals, Inc., dated March 14, 2018 (incorporated by reference to Exhibit 10.1 to the
Companys Current Report on Form 8-K filed on March 15, 2018)
|
|
|
(d)(5)
|
|
Stock Purchase Agreement by and between Akcea Therapeutics, Inc. and Ionis Pharmaceuticals, Inc., dated March 14, 2018 (incorporated by reference to Exhibit 10.2 to the Companys Current Report on Form 8-K filed on March 15, 2018)
|
|
|
(d)(6)#
|
|
Development, Commercialization and License Agreement by and among Akcea Therapeutics, Inc. and Ionis Pharmaceuticals, Inc., dated December 18, 2015 (incorporated by reference to Exhibit 10.4 to the Companys Registration
Statement on Form S-1 filed on March 27, 2017)
|
|
|
(d)(7)#
|
|
Strategic Collaboration, Option and License Agreement by and among Akcea Therapeutics, Inc. and Novartis Pharma AG, dated January 5, 2017 (incorporated by reference to Exhibit 10.7 to the Companys Registration Statement
on Form S-1 filed on March 27, 2017)
|
|
|
(d)(8)#
|
|
Letter Agreement regarding Development, Commercialization and License Agreement between Akcea Therapeutics, Inc. and Ionis Pharmaceuticals, Inc., dated January 18, 2017 (incorporated by reference to Exhibit 10.15 to the
Companys Registration Statement on Form S-1 filed on March 27, 2017)
|